These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 6189286

  • 1. Inhibition of glycosylation of herpes simplex virus glycoproteins: identification of antigenic and immunogenic partially glycosylated glycopeptides on the cell surface membrane.
    Glorioso J, Szczesiul MS, Marlin SD, Levine M.
    Virology; 1983 Apr 15; 126(1):1-18. PubMed ID: 6189286
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.
    Glorioso J, Schröder CH, Kumel G, Szczesiul M, Levine M.
    J Virol; 1984 Jun 15; 50(3):805-12. PubMed ID: 6328010
    [Abstract] [Full Text] [Related]

  • 3. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA, Marlin SD, Schwartz SA, Glorioso JC.
    J Immunol; 1984 Oct 15; 133(4):2206-14. PubMed ID: 6206157
    [Abstract] [Full Text] [Related]

  • 4. Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes.
    Glorioso J, Kees U, Kümel G, Kirchner H, Krammer PH.
    J Immunol; 1985 Jul 15; 135(1):575-82. PubMed ID: 2582051
    [Abstract] [Full Text] [Related]

  • 5. Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.
    Holland TC, Marlin SD, Levine M, Glorioso J.
    J Virol; 1983 Feb 15; 45(2):672-82. PubMed ID: 6187935
    [Abstract] [Full Text] [Related]

  • 6. Effect of tunicamycin on the synthesis of herpes simplex virus type 1 glycoproteins and their expression on the cell surface.
    Norrild B, Pedersen B.
    J Virol; 1982 Aug 15; 43(2):395-402. PubMed ID: 6180176
    [Abstract] [Full Text] [Related]

  • 7. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
    Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, Krummenacher C, Eisenberg RJ, Cohen GH.
    J Virol; 2014 Nov 15; 88(21):12612-22. PubMed ID: 25142599
    [Abstract] [Full Text] [Related]

  • 8. Relatedness of glycoproteins expressed on the surface of simian herpes-virus virions and infected cells to specific HSV glycoproteins.
    Eberle R, Black D, Hilliard JK.
    Arch Virol; 1989 Nov 15; 109(3-4):233-52. PubMed ID: 2482016
    [Abstract] [Full Text] [Related]

  • 9. Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.
    Rosenthal KL, Smiley JR, South S, Johnson DC.
    J Virol; 1987 Aug 15; 61(8):2438-47. PubMed ID: 3037106
    [Abstract] [Full Text] [Related]

  • 10. Herpes simplex virus glycoproteins: isolation of mutants resistant to immune cytolysis.
    Machtiger NA, Pancake BA, Eberle R, Courtney RJ, Tevethia SS, Schaffer PA.
    J Virol; 1980 May 15; 34(2):336-46. PubMed ID: 6246268
    [Abstract] [Full Text] [Related]

  • 11. Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.
    Norrild B, Shore SL, Nahmias AJ.
    J Virol; 1979 Dec 15; 32(3):741-8. PubMed ID: 229263
    [Abstract] [Full Text] [Related]

  • 12. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
    Kitamura K, Namazue J, Campo-Vera H, Ogino T, Yamanishi K.
    Virology; 1986 Feb 15; 149(1):74-82. PubMed ID: 2418583
    [Abstract] [Full Text] [Related]

  • 13. The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections.
    Eberle R, Mou SW, Zaia JA.
    J Med Virol; 1985 Jun 15; 16(2):147-62. PubMed ID: 2409225
    [Abstract] [Full Text] [Related]

  • 14. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM, Huang ZY, Gallagher JR, Lin Y, Lou H, Whitbeck JC, Wald A, Cohen GH, Eisenberg RJ.
    J Virol; 2015 Sep 15; 89(18):9213-31. PubMed ID: 26109729
    [Abstract] [Full Text] [Related]

  • 15. Differential immunologic reactivity and processing of glycoproteins gA and gB of herpes simplex virus types 1 and 2 made in Vero and HEp-2 cells.
    Pereira L, Dondero D, Norrild B, Roizman B.
    Proc Natl Acad Sci U S A; 1981 Aug 15; 78(8):5202-6. PubMed ID: 6272294
    [Abstract] [Full Text] [Related]

  • 16. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
    Kümel G, Kaerner HC, Levine M, Schröder CH, Glorioso JC.
    J Virol; 1985 Dec 15; 56(3):930-7. PubMed ID: 2415719
    [Abstract] [Full Text] [Related]

  • 17. A rapid procedure for the enrichment of undenaturated, antigenically active herpes simplex virus glycoproteins.
    Respess RA, Pancake BA, Edson CM, Schaffer PA.
    J Virol Methods; 1984 Feb 15; 8(1-2):27-45. PubMed ID: 6200489
    [Abstract] [Full Text] [Related]

  • 18. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL, Duncan BE, Raybould TJ, Watson DH.
    J Gen Virol; 1985 May 15; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [Abstract] [Full Text] [Related]

  • 19. Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies.
    Pereira L, Hoffman M, Tatsuno M, Dondero D.
    Virology; 1984 Nov 15; 139(1):73-86. PubMed ID: 6208685
    [Abstract] [Full Text] [Related]

  • 20. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH, Oakes JE, Lausch RN.
    Invest Ophthalmol Vis Sci; 1993 Jul 15; 34(8):2460-8. PubMed ID: 8392037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.